ANP Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week -0.01 -20.00
Close 0.04 1 Month 0.00 0.00
Volume 220000 1 Year -0.03 -42.86
52 Week High 0.08
52 Week Low 0.03
ANP Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
AKK 0.01 0.00%
TON 0.09 -10.00%
TON 0.09 -10.00%
TON 0.09 -10.00%
FAR 0.07 0.00%
FAR 0.07 0.00%
FAR 0.07 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
OMH 0.18 28.57%
SRZ 0.05 25.00%
SRZ 0.05 25.00%
HGO 0.05 25.00%
HGO 0.05 25.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
GBA 0.02 -33.33%
DAU 0.02 -33.33%
More..

Antisense Therapeutics Ltd (ASX: ANP)

ANP Technical Analysis 4
As on 7th Dec 2016 ANP Share Price closed @ 0.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.05 & Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
ANP Target for December
1st Target up-side 0.06
2nd Target up-side 0.07
3rd Target up-side 0.08
1st Target down-side 0.04
2nd Target down-side 0.03
3rd Target down-side 0.02
ANP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.antisense.com.au
ANP Address
ANP
6 - 8 Wallace Avenue
Toorak, VIC 3142
Australia
Phone: 61 3 9827 8999
Fax: 61 3 9827 1166
Interactive Technical Analysis Chart Antisense Therapeutics Ltd ( ANP ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Antisense Therapeutics Ltd
ANP Business Profile
Antisense Therapeutics Limited develops and commercializes novel antisense therapeutics in the United States, Canada, Japan, Australia, and Europe. The company’s product pipeline comprises ATL1103, a Phase II clinical trial drug to block growth hormone receptor expression and reduce the levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action, including acromegaly, diabetic retinopathy, diabetic nephropathy, and various cancers. Its product pipeline also includes ATL1102 as a Phase II antisense inhibitor of CD49d to treat multiple sclerosis; a research stage antisense compound targeting the VLA-4 molecule for the treatment of asthma; and a preclinical stage product for stem cell mobilization in stem cell transplantation, as well as ATL1101, a preclinical stage antisense inhibitor of insulin like growth factor 1 receptor for the treatment of prostate cancer. The company has strategic alliance and license agreement with Tianjin International Joint Academy of Biotechnology and Medicine for the development and commercialization of ATL1102, as well as strategic partnership with Isis Pharmaceuticals Inc. to access antisense technology. Antisense Therapeutics Limited is based in Toorak, Australia.